Form 4: Amicus Therapeutics CPO Sells Shares Under 10b5-1 Plan

Amicus Therapeutics' Chief People Officer, David Michael Clark, sold 25,643 shares of common stock for approximately $9.51 per share under a pre-arranged 10b5-1 trading plan.

Summary

• David Michael Clark, Chief People Officer of Amicus Therapeutics, Inc. (FOLD), sold 25,643 shares of common stock.
• The transaction occurred on November 4, 2025, at a weighted average price of $9.5098 per share, with prices ranging from $9.50 to $9.54.
• Following this sale, Mr. Clark beneficially owns 322,618 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Clark on March 14, 2025.

Sentiment

Score: 5

Explanation: A neutral score. While an insider sale can be perceived negatively, the execution under a pre-arranged 10b5-1 plan mitigates concerns about opportunistic trading, making it a routine event for an executive managing their personal finances.

Positives

• NA

Negatives

• An insider, the Chief People Officer, sold a significant number of shares (25,643) of company stock.
• While executed under a 10b5-1 plan, insider sales can sometimes be perceived as a lack of confidence in the company's near-term prospects, though this is mitigated by the pre-planned nature.

Risks

• Potential negative investor sentiment due to an insider sale, even if pre-planned, which could put slight downward pressure on the stock price.

Future Outlook

NA

Industry Context

This is an individual insider transaction and does not directly reflect broader industry trends. However, insider activity in biotechnology companies like Amicus Therapeutics is often closely watched by investors for signals regarding company performance or future prospects.

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: May interpret the insider sale, even if pre-planned, with caution, potentially leading to minor negative sentiment. However, the 10b5-1 plan reduces the likelihood of significant impact.
• Employees: No direct impact from this filing.
• Customers/Suppliers/Creditors: No direct impact from this filing.

Next Steps

• NA

Key Dates

Recommendation

The insider sale by the Chief People Officer, while a notable event, was executed under a pre-arranged 10b5-1 trading plan. This suggests a planned diversification or liquidity event rather than a reaction to new material non-public information. Without additional context on company performance or strategic shifts, this single transaction does not warrant a change in investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Amicus Therapeutics, FOLD, Insider Trading, Form 4, Stock Sale, David Michael Clark, Chief People Officer, 10b5-1 Plan, Equity Transaction